PPARγ agonists have many beneficialeffects combined with their independent antiatherosclerotic actions and theirimportant effects on dyslipidemia and insulin resistance in the medication ofkidney disease coupled to diabetes [10, 12–15, 21, 82].Activation of PPARγ attenuates diabeticglomerulonephritis due to its anti-inflammatory and profibrotic effects [32–35]. Here, PPARG is linked to metabolic syndrome.